Inspira Technologies announced the strategic commercial showcase of its FDA-cleared INSPIRA ART100 system at the AmSECT 64th International Conference. The system targets clinical decision-makers and leverages its FDA clearance for immediate clinical integration. The presentation with U.S. distributor Glo-Med Networks Inc. highlights an active commercial pipeline, moving towards sales execution. This event marks a key phase in the company’s U.S. commercial strategy to expand clinical partnerships and distribution footprint. Interested parties can schedule a meeting with Global VP Sales, Mike Hershkovitz, during the conference. The AmSECT International Conference is scheduled for March 25–29, 2026, in Austin, Texas, showcasing cutting-edge medical technologies in extracorporeal circulation and patient care. Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with its FDA-cleared INSPIRA ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. The company is also developing the INSPIRA ART500 system and HYLA blood sensor platform. For more information, visit: https://inspira-technologies.com.

Read more at GlobeNewswire: Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared